一、人才项目
2020年,复旦大学卓识人才培育计划
2016年,国家青年高层次人才计划
二、研究方向
1)肿瘤免疫治疗耐药的药理学机制;
2)肿瘤免疫治疗新药开发。
三、科研项目
2018,上海市科委科研计划项目,“Wnt信号通路调控的肿瘤免疫微环境在结肠癌免疫抵抗的研究”,主持
2018,上海市科委科研计划项目,“结肠癌靶向EPCAM1通用型CART细胞治疗研究”,参与
2018,复旦大学自主研究课题融合基金,“Fzd4在肿瘤干细胞中的研究和新抑制剂开发”,主持
2019,国家自然科学基金面上项目,“用于癌症免疫治疗新型RORγt激动剂的设计合成与作用机制研究”,参与
2019,国家自然科学基金面上项目,“Wnt信号通路抑制剂调控肿瘤免疫微环境的机制研究”,主持
2019,上海市科委生物医药领域科技支撑项目,“新型癌症免疫治疗药物RORγt激动剂YWRQ-16的临床前研究”,参与
2019,复旦大学-中国科学院上海药物研究所融合基金项目,“基于单细胞测序技术的肝癌细胞图谱解析及新型生物标记物的发现和鉴定”,主持
2019,复旦大学“卓越2025”人才培育计划卓识计划,主持
2020,上海市科委“科技创新行动计划”国际合作项目,“新型亲环素抑制剂抗新型冠状病毒的研究”,主持
2021,复旦大学先导项目,结肠癌免疫治疗关键技术研究,主持
2021,国家自然科学基金面上项目,“BCL9/9L调节T细胞的肿瘤浸润改善PD-1治疗耐药的研究”,主持
四、讲授课程
本科生课程:
药理学、药理学C、MBBS(药理学)、口腔临床药物学、药学分子生物学、生物化学
研究生课程:
高级药理学进展、高级临床药理学、高级神经药理学、药学进展
五、获得奖项
2024年 复旦大学优秀博士学位论文指导导师
2024年 第三十五届上海市优秀发明选拔赛优秀发明铜奖
2023年 中国抗癌协会科技奖二等奖
2022年 上海生物工程学会“东富龙”生物工程优秀青年科学家奖
2019年 增爱·长木学术奖,增爱中国基金会
2010年 欧洲生物化学学会联盟, FEBS Youth Travel Fellowship
六、学术兼职
中国药理学会化药专业委员会专业委员;
上海市生物工程学会细胞治疗专业委员会专家委员
中国抗癌协会会员;
上海市药理学会会员
上海市药学会会员
七、代表性论文
Zhang H; Liu C; Chen Q; Shen L; Xiao W; Li J; Wang Y*; Zhu D*; Zhang Q*; Li J*.Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β Catenin/B-Cell Lymphoma 9 (BCL9) Interaction as a Single Agent and in Combination with Anti-PD-1 Antibody for the Treatment of Colorectal Cancer, J. Med. Chem, 2023, 66(2):1349-1379. (IF: 7. 3)
Shen L; Peng X; Bao Y; Liu C; Zhang H; Li J; Zhu D*. Zhang Q*. Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein−protein interaction inhibitors, Eur. J. Med. Chem, 2023, 247:115075. (IF: 6. 7)
Zhang H; Liu C; Zhu D*; Zhang Q*; Li J*. Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin Interactions with Its Nuclear Partners, J. Med. Chem, 2023, 66(1):1-31. (IF: 7. 3)
Xu Y; Wei Z; Feng M; Zhu D; Mei S; Wu Z; Feng Q; Chang W; Ji M; Liu C; Zhu Y; Shen L; Yang F; Chen Y; Feng Y; Xu J*; Zhu D*.Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers,Cell Rep.,2022 40(9):1-25. (IF: 9. 9)
Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., Zhu, Y., Huang, C., Yang, X., Shi, Y., Qiu, S., Sun, H., Zhu, A., Zhou, J., Xu, Y., Zhu, D.*, Fan, J.* Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov., 2022. DOI: 10.1158/2159-8290.CD-21-1022 (IF: 39.4)
Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., Xie, D., Zhu, D.* RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers. J Exp Clin Canc Res. 2022. DOI : 10.1186/s13046-022-02289-2 (IF: 11.3)
Feng, M., Wu, Z., Zhou, Y., Wei, Z., Tian, E., Mei, S., Zhu, Y., Liu, C., He, F., Li, H., Xie, C., Jin, J., Dong, J., Yang, D., Yu, K., Qian, J., Lambrechts, D.*, Wang, M.*, Zhu, D.* BCL9 regulates CD226 and CD96 checkpoints in CD8+ T c ells to improve PD-1 response in cancer. Signal Transduct Target Ther, 2021, 6, 313. (5 year IF: 39.3)
Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y., Rosin-Arbesfeld, R., Shi, Y., Zhou, Y., Yang, M., Feng, Y., Jiang, Y., Shao, Z., Yu, K.*, Zhu, D.* BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene, 2021, 40: 2982- 2997. (IF: 8.0)
Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y.*, Zhu, D.* Discovery of a novel, potent, and selective small-molecu le inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy. Br. J. Pharmacol., 2021, 178(13): 2651-2670. (IF: 8.7)
Tian, E., Yu, M., Feng, M., Wang, Y., Xie, Q.*, Zhu, D.* RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer. Pharmacol.Res., 2021, 172:105793. (IF: 9. 3)
Feng, M., Zhao, Z., Yang, M., Ji, J., Zhu, D.*, T-cell-based immunotherapy in colorectal cancer. Cancer Lett., 2021, 498(40): 201-209. (IF., 9.7)
Feng, M., Jin, J., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Raf, S., Zhu, A., Feng, Y.*, Zhu, D.* Pharmacolo gical inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockad es by modulating Treg cells. Sci. Adv., 2019, 5(5): 1-16. (IF: 14.1)
Zhu, D., Wang, Z., Zhao, J., Calimeri, T., Meng, J., Hideshima, T., Fulciniti, M., Kang, Y., Ficarro, S., Tai, Y., Hunter, Z., McMilin, D., Tong, H., Mitsiades, C., Wu, C., Treon, S., Dorfman, D., Pinkus, G., Munshi, N., Tassone, P., Marto, J., Anderson, K., Carrasco, R.* The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med., 2015, 21(6): 572-580. (IF: 53.4)
Takada, K.#, Zhu, D.#, Bird, GH. #, Sukhdeol, K., Zhao, J., Mani, M., Lemieux, M., Carrasco, D., Ryan, J., Horst, D., Fulciniti, M., Mushi, NC., Xu, W., Kung, AL., Shivdasani, R., Walensky, L.*, Carrasco, R.* Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling. Sci Transl Med., 2012, 4(148): 1-13. (IF: 17.9 )
八、代表性专利
1)一种具有苄氧基芳环结构的化合物,其制备方法和用途,中国,ZL202010591651.0
2)EpCAM-CAR-T和hsBCL9CT-24的组合物在制备抗肿瘤药物中的应用,中国,ZL202011371360.4
3)一种RORγ激动剂及其在制备治疗肿瘤疾病药物以及促进Type17细胞分化,中国,ZL202110675290.X
4)一种 CAR-T 治疗载体及其构建方法和应用,中国,ZL202110333104.4
5)β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用,中国,202111392206.X
6)嵌合抗原受体及其衍生物和应用,中国,PCT/CN2022/122211